Craft

AxoGen

Stock Price

$14

2024-10-29

Market Capitalization

$611.9 M

2024-10-29

Revenue

$225.2 M

FY, 2025

AxoGen Summary

Company Summary

Overview
AxoGen is a biotech company developing treatment options for the reconstruction and repair of peripheral nerve injuries. It is passionate about restoring nerve function and quality of life to patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body.AxoGen's portfolio of products includes Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves, AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments and Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a soft tissue covering to reduce inflammation and scar tissue formation. 
Type
Public
Status
Active
Founded
2002
HQ
Alachua, FL, US | view all locations
Website
http://www.axogeninc.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Amy Wendell

    Amy Wendell, Lead Director

    • Quentin S. Blackford

      Quentin S. Blackford, Director

      • Gregory G. Freitag

        Gregory G. Freitag, Special Counsel

      • Mark Gold

        Mark Gold, Director

        LocationsView all

        2 locations detected

        • Alachua, FL HQ

          United States

          13631 Progress Blvd #400

        • Burleson, TX

          United States

          300 Boone Rd

        AxoGen Financials

        Summary Financials

        Revenue (Q1, 2026)
        $61.5M
        Gross profit (Q1, 2026)
        $46.2M
        Net income (Q1, 2026)
        ($19.6M)
        Cash (Q1, 2026)
        $82.7M
        EBIT (Q1, 2026)
        ($2.8M)
        Enterprise value
        $529.2M

        Footer menu